產(chǎn)后1年內(nèi)，由于子宮復(fù)舊和哺乳因素，女性生殖內(nèi)分泌功能發(fā)生較大變化。產(chǎn)后1年內(nèi)意外妊娠可嚴(yán)重影響婦女健康。目前國內(nèi)外主要產(chǎn)后避孕方法包括哺乳期閉經(jīng)避孕法(LAM)、屏障避孕法、宮內(nèi)節(jié)育器(IUD)、激素避孕法及結(jié)扎避孕等。由于國內(nèi)產(chǎn)后避孕尚未規(guī)范、系統(tǒng)化，因此，有效避免產(chǎn)后意外妊娠、降低高危人工終止妊娠術(shù)發(fā)生率及提高產(chǎn)后女性生殖健康是計(jì)劃生育工作的重點(diǎn)。

Postpartum is a special period of the women's life when women have lots of changes in endocrine system, and therefore the undesired pregnancy during postpartum has serious influence on women's health.For now, the main methods of postpartum contraception at home and abroad including the lactational amenorrhea contraception(LAM), barrier contraception, intrauterine devices(IUD), hormonal contraception, ligation contraception and so on.However, there is no standard postpartum contraceptive system in China, How to reduce the undesired pregnancy during one year after postpartum, decrease the high risk abortions and promote the maternal and child health are the focus of family planning work.

[1]

Huang YM.Postpartum contraception[J].Chin J Pract Gynecol Obstertr, 2009, 25(10):731-733.

[2]

Tsui AO, Wasserheit JN, Haaga J.Reproductive health in developing countries: Expanding dimens[M].Washington DC:National Academy Press, 1997, 40-84.

[3]

Grisaru-Granovsky S, Gordon E, Haklai Z, et al.Effect of interpregnancy interval on adverse perinatal outcomes:A national study[J].Contraception, 2009, 80:512-518.

[4]

Conde-Agudelo A, Belizan JM.Maternal morbidity and mortality associated with interpregnancy interval:A cross-sectional study[J].BMJ, 2000, 321:1255-1259.

[5]

World Health Organization.Report of a WHO technical consultation on birth spacing[R].Geneva:WHO Press, 2005:1-48.

[6]

Huang YM, Kang JZ, Chen RZ, et al. Status of contraceptive adoption and service demand among postpartum women: A survey in Shanghai centre communities[J].Chin J Fam Plann, 2007, 141(7):501.

[7]

Chen CP.The Zhejiang countryside post-natal contraception condition and the birth control service investigates[J].Chin Man Rehabil Med, 2010, 1(5):120-121.

[8]

Centers for Disease Control and Prevention(CDC). Contraceptive use among postpartum women-12 states and New York City, 2004-2006[J].MMWR Morb Mortal Wkly Rep, 2009, 58(30):821-826.

[9]

DaVanzo J, Hale L, Razzaque A, et al.Effects of interp regnancyinterval and outcome of the preceding pregnancy on pregnancy outcomes in Matlab, Bangladesh[J].BJOG, 2007, 114(9):1079-1087.

[10]

Diaz S, Croxatto HB. Contraception in lactating women[J].Curr Opin Obstet Gynecol, 1993, 5:818-22.

[11]

Kennedy KI, Trussell J.Postpartum contraception and lactation//Hatcher RA, Trussell J, Nelson AL, et al.Contraceptive technology.19th ed[M].New York: Ardent Media, 2007:403-431.

[12]

Vekemans M.Postpartum contraception:The lactational amenorrhoea method[J].Eur J Contracep Reprod Health Care, 1997, 2(2):105-111.

[13]

World Health Organization.Department of Reproductive Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs(CCP), INFO project.Family planning:A global handbook for providers[M].Baltimore and Geneva:CCP and WHO, 2007, 1-372.

[14]

Xu JX, Shi TL, Zhou XB, et al.Contraceptive efficacy of bioadhesive nonoxynol-9 gel:Comparison with nonoxynol-9 suppository[J].Chin J Obstet Gynecol, 2003, 38(10):629-631.

[15]

Zhao HX, Wu JQ, Li YY, et al.Selection and use of contraceptive methods among internal migrant workers in three large Chinese cities: A workplace-based survey[J]. Eur J Contracept Reprod Health Care, 2011, 16(4):277-88.

[16]

Chi IC, Farr G.Postpartum IUD contraception:A review of an international experience[J].Adv Contracept, 1989, 5(3):127-146.

[17]

FFPRHC Guidance.Contraceptive choices for breastfeeding women[J].J Fam Plann Reprod Health Care, 2004, 30(3):181-189.

[18]

Farley TM, Rosenburg MJ, Rowe PJ, et al.Intrauterine devices and pelvic inflammatory disease: An international perspective[J].Lancet, 1992, 339:785-788.

[19]

Xu JX, Reusche C, Burdan A.Immediate postplacental insertion of the intrauterine device:A review of Chinese and the world's experiences[J].Adv Contracept, 1994, 10(1):71-82.

[20]

Min L, Xu KH.Clinical investigation of levonorgestrel-releasing intrauterine system[J/CD].Chin J Obstet Gynecol Pediatr:Electron Ed, 2012, 8(3):335-336.

[21]

World Health Organization.Statement:Progestogen-only contraceptive use during lactation and its effects on the neonate[R].Geneva:WHO Press, 2008.

[22]

Kapp N, Curtis K, Nanda K.Progestogen-only contraceptive use among breastfeeding women:A systematic review[J].Contraception, 2010, 82(1):17-37.

[23]

World Health Organization.Technical consultation on hormonal contraceptiveuse during lactation and effects on the newborn:Summary report[R].Geneva:WHO Press, 2010.

[24]

Costa ML, Cecatti JG, Krupa FG, et al.Progestin-only contraception prevents bone loss in postpartum breastfeeding women[J].Contraception, 2012, 85(4):374-80.

[25]

Liu CD, Weng LJ.Pure progestin contraceptive the safety and efficacy:The epidemiological view[J].Foreign Med Fam Plan, 1994, 13(1):28-30.

[26]

WHO Task Force on Oral Contracep tives.Effects of hormonal conracep tives on breastmilk composition and infant growth[J].Stud Fam Plann, 1988, 19(6):361-369.

[27]

Hannon PR, Duggan AK, Serwint JR, et al.The influence of medroxyprogesterone on the duration of breast-feeding in mothers in an urban community[J].Arch Pediatr Adolesc Med, 1997, 151(5):490-496.

[28]

Kaunitz AM.Injectable depot medroxyprogesterone acetate contraception-an update for U.S. clinicians[J].Int J Fertil Women's Med, 1998, 43:73-83.

[29]

Templeman CL, Cook V, Goldsmith LJ, et al.Postpartum contraceptive use among adolescent mothers[J].Obstet Gynecol, 2000, 95(5):770-776.

[30]

Qiao YH, Fang HL, Jiang LF.150 cases of lactation women with acetic acid medroxyprogesterone acetate of acceptability and evaluation[J].Clin Med, 2005, 08:39-40.

[31]

Isley MM, Edelman A.Contraceptive implants:An overview and update[J].Obstet Gynecol Clin North Am, 2007, 34(1):73-90.

[32]

Tu P, Qiu S, Fang H, et al.Acceptance, efficacy, and side effects of Norplant implants in four counties in north China[J].Stud Fam Plann, 1997, 28(2):122-131.

[33]

World Health Organization.Medical eligibility criteria for contraceptive Use[R].Geneva:WHO press, 2000.

[34]

Truitt ST, Fraser AB, Grimes DA, et al.Hormonal contraception during lactation:Systematic Review of randomized controlled trials[J].Contraception, 2003, 68:233-238.

[35]

Jackson E.Controversies in postpartum contraception:When is it safe to start oral contraceptives after childbirth[J]? Thromb Res, 2011, 127 (3):35-39.

[36]

Huang ZR, Wu SC.Oral contraceptive development and the present condition of the usage[J].J Int Reprod Health/Fam plan, 2009, 28(3):139-141.

[37]

Gainer E, Massai R, Lillo S, et al. Levonorgestrel pharmacokinetics in plasma and milk of lactating women who take 1.5 mg for emergency contraception[J].Hum Reprod, 2007, 22(6):1578-1584.

[38]

Cheng LN.Postpartum contraceptive technology progress[J].Chin J Pract Gynecol Obstertr, 2001, 17(9):516-518.

[1]周夢玲, 薛志偉, 周淑. 妊娠合并子宮肌瘤的孕期變化及其與不良妊娠結(jié)局的關(guān)系[J]. 中華婦幼臨床醫(yī)學(xué)雜志(電子版), 2023, 19(05): 611-615.[2]居曉慶, 金蘊(yùn)潔, 王曉燕. 剖宮產(chǎn)術(shù)后瘢痕子宮患者再次妊娠陰道分娩發(fā)生子宮破裂的影響因素分析[J]. 中華婦幼臨床醫(yī)學(xué)雜志(電子版), 2023, 19(05): 575-581.[3]陳莉, 雷雪芹, 段煉, 曾悅, 何國琳. 影響2次剖宮產(chǎn)術(shù)后陰道試產(chǎn)產(chǎn)婦試產(chǎn)成功因素及妊娠結(jié)局分析[J]. 中華婦幼臨床醫(yī)學(xué)雜志(電子版), 2023, 19(03): 287-294.[4]吳晶晶, 胡倩, 李華鳳. 圍產(chǎn)期焦慮/抑郁與分娩疼痛相關(guān)性的研究現(xiàn)狀[J]. 中華婦幼臨床醫(yī)學(xué)雜志(電子版), 2023, 19(02): 156-161.[5]沈立平, 龍馭云, 楊月華, 張敏, 許陽, 趙亞麗, 李靜, 張昀, 江世文, 孫志明. 不同避孕方式對(duì)女性再次受孕的影響因素分析[J]. 中華婦幼臨床醫(yī)學(xué)雜志(電子版), 2023, 19(01): 107-112.[6]趙春桃, 梁峰雪, 楊瑞敏, 陳云璇, 陳曦, 焦桂清. 三維盆底超聲預(yù)測產(chǎn)婦發(fā)生盆腔臟器脫垂的價(jià)值及影響因素[J]. 中華婦幼臨床醫(yī)學(xué)雜志(電子版), 2022, 18(05): 606-614.[7]朱麗麗, 李冰, 薛靜, 于慧, 李淑紅. 椎管內(nèi)分娩鎮(zhèn)痛對(duì)經(jīng)陰道分娩初產(chǎn)婦產(chǎn)后早期盆底功能的影響[J]. 中華婦幼臨床醫(yī)學(xué)雜志(電子版), 2022, 18(04): 484-491.[8]李炳根, 龔獨(dú)輝, 賴澤如, 聶向陽. 產(chǎn)后腹直肌分離全腔鏡下肌后/腹膜外補(bǔ)片修補(bǔ)術(shù)的臨床研究[J]. 中華疝和腹壁外科雜志(電子版), 2023, 17(06): 724-727.[9]朱琳, 劉寧. 地諾孕素治療復(fù)發(fā)性卵巢子宮內(nèi)膜異位囊腫的臨床研究[J]. 中華臨床醫(yī)師雜志(電子版), 2022, 16(06): 519-523.[10]唐?, 唐卉, 陳悅, 李慕軍. 前置胎盤剖宮產(chǎn)改良術(shù)式預(yù)防產(chǎn)后出血的探討[J]. 中華臨床醫(yī)師雜志(電子版), 2022, 16(05): 436-441.[11]王永, 李霞林, 楊蓉, 潘康妮, 余琳, 王偉偉, 孫雯, 陳敦金. 胎盤植入合并嚴(yán)重產(chǎn)后出血輸血方案的研究[J]. 中華產(chǎn)科急救電子雜志, 2023, 12(03): 173-179.[12]趙先蘭, 周艷. 胎盤植入性疾病出血血管介入治療策略[J]. 中華產(chǎn)科急救電子雜志, 2023, 12(03): 147-150.[13]肖美群, 朱薇, 符華影. 產(chǎn)后急性子宮內(nèi)翻四例臨床分析[J]. 中華產(chǎn)科急救電子雜志, 2023, 12(02): 113-117.[14]黃暢曉, 李力. 預(yù)防產(chǎn)后出血關(guān)口前移的策略[J]. 中華產(chǎn)科急救電子雜志, 2022, 11(04): 198-201.[15]溫潔, 陳丹青. 妊娠合并缺鐵性貧血與產(chǎn)后出血的管理[J]. 中華產(chǎn)科急救電子雜志, 2022, 11(04): 217-221.閱讀次數(shù)全文

0

HTMLPDF最新錄用 在線預(yù)覽 正式出版最新錄用 在線預(yù)覽 正式出版 0 0 0 0 0 0

摘要

13

 來源 本網(wǎng)站其他網(wǎng)站   次數(shù)76  比例54%46%

相關(guān)知識(shí)

產(chǎn)后避孕的應(yīng)用進(jìn)展
孕產(chǎn)婦產(chǎn)前健康教育的研究進(jìn)展
研究進(jìn)展
孕期體重管理的研究進(jìn)展
延續(xù)護(hù)理在產(chǎn)婦產(chǎn)褥期的研究進(jìn)展
孕產(chǎn)婦分娩心理創(chuàng)傷的研究進(jìn)展
孕產(chǎn)婦分娩準(zhǔn)備度的研究進(jìn)展
避孕器與計(jì)劃生育政策的研究
孕婦孕期體重控制的研究進(jìn)展
孕期睡眠障礙的流行病學(xué)研究進(jìn)展

網(wǎng)址: 產(chǎn)后避孕的研究進(jìn)展 http://www.u1s5d6.cn/newsview379554.html